• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.进一步探索 M₁别构激动剂:细微的结构变化会消除 M₁别构激动作用,并导致pan-MAChR 正构拮抗剂作用。
Bioorg Med Chem Lett. 2013 Jan 1;23(1):223-7. doi: 10.1016/j.bmcl.2012.10.132. Epub 2012 Nov 9.
2
Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M₁ muscarinic acetylcholine receptor.反向工程选择性激动剂 TBPB 揭示了 M₁ 毒蕈碱乙酰胆碱受体的变构和变构作用模式。
Mol Pharmacol. 2013 Sep;84(3):425-37. doi: 10.1124/mol.113.087320. Epub 2013 Jun 24.
3
Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.化学修饰 M(1)激动剂 VU0364572 揭示了药理学中的分子开关和双位结合模式。
ACS Chem Neurosci. 2012 Dec 19;3(12):1025-36. doi: 10.1021/cn300103e. Epub 2012 Sep 9.
4
Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor.新型 M1 毒蕈碱型乙酰胆碱受体选择性激动剂的变构和变构外作用模式。
Mol Pharmacol. 2010 Jul;78(1):94-104. doi: 10.1124/mol.110.064345. Epub 2010 Apr 22.
5
The M1 muscarinic receptor allosteric agonists AC-42 and 1-[1'-(2-methylbenzyl)-1,4'-bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site.M1 毒蕈碱型乙酰胆碱受体变构激动剂 AC-42 和 1-[1'-(2-甲基苄基)-1,4'-联哌啶-4-基]-1,3-二氢-2H-苯并咪唑-2-酮与乙酰胆碱正位构象结合位点不同的独特结合位点结合。
Mol Pharmacol. 2010 Oct;78(4):648-57. doi: 10.1124/mol.110.065771. Epub 2010 Jul 21.
6
Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats.新型M1毒蕈碱型乙酰胆碱受体选择性变构激活剂可调节淀粉样蛋白加工并在大鼠中产生抗精神病样活性。
J Neurosci. 2008 Oct 8;28(41):10422-33. doi: 10.1523/JNEUROSCI.1850-08.2008.
7
Bitopic Binding Mode of an M Muscarinic Acetylcholine Receptor Agonist Associated with Adverse Clinical Trial Outcomes.M 型乙酰胆碱受体激动剂的双结合模式与不良临床试验结局相关。
Mol Pharmacol. 2018 Jun;93(6):645-656. doi: 10.1124/mol.118.111872. Epub 2018 Apr 25.
8
Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation.变构激动剂和正构激动剂对M1毒蕈碱型乙酰胆碱受体内化和下调的对比作用。
J Pharmacol Exp Ther. 2009 Dec;331(3):1086-95. doi: 10.1124/jpet.109.160242. Epub 2009 Sep 18.
9
Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties.M1变构激动剂TBPB类似物的合成与构效关系。第一部分:苄基替代物和优势结构部分的探索。
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5439-42. doi: 10.1016/j.bmcl.2008.09.023. Epub 2008 Sep 10.
10
Probing the binding site of novel selective positive allosteric modulators at the M muscarinic acetylcholine receptor.探究新型选择性正变构调节剂在 M 型毒蕈碱乙酰胆碱受体上的结合位点。
Biochem Pharmacol. 2018 Aug;154:243-254. doi: 10.1016/j.bcp.2018.05.009. Epub 2018 May 17.

引用本文的文献

1
Diverse Effects on M Signaling and Adverse Effect Liability within a Series of M Ago-PAMs.一系列Mago-PAM对M信号传导的不同影响及不良反应倾向
ACS Chem Neurosci. 2017 Apr 19;8(4):866-883. doi: 10.1021/acschemneuro.6b00429. Epub 2017 Jan 10.
2
Discovery and SAR of a novel series of potent, CNS penetrant M4 PAMs based on a non-enolizable ketone core: Challenges in disposition.基于不可烯醇化酮核心的新型强效、可穿透中枢神经系统的M4型正变构调节剂系列的发现与构效关系:处置方面的挑战
Bioorg Med Chem Lett. 2016 Sep 1;26(17):4282-6. doi: 10.1016/j.bmcl.2016.07.042. Epub 2016 Jul 21.
3
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine core.基于5,6-二甲基-4-(哌啶-1-基)噻吩并[2,3-d]嘧啶核心的新型系列高中枢神经系统渗透性M4型正变构调节剂的发现与优化
Bioorg Med Chem Lett. 2016 Jul 1;26(13):3029-3033. doi: 10.1016/j.bmcl.2016.05.010. Epub 2016 May 5.
4
Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors.GPCR变构调节剂发现中的实用策略与概念:代谢型谷氨酸受体的最新进展
Chem Rev. 2016 Jun 8;116(11):6707-41. doi: 10.1021/acs.chemrev.5b00656. Epub 2016 Feb 16.
5
2013 Philip S. Portoghese Medicinal Chemistry Lectureship: drug discovery targeting allosteric sites.2013年菲利普·S·波托盖斯药物化学讲座:靶向变构位点的药物发现
J Med Chem. 2014 Sep 25;57(18):7485-98. doi: 10.1021/jm5011786. Epub 2014 Sep 15.
6
Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.M1毒蕈碱型乙酰胆碱受体的变构调节:改善认知及对精神分裂症和阿尔茨海默病的潜在治疗作用
Drug Discov Today. 2013 Dec;18(23-24):1185-99. doi: 10.1016/j.drudis.2013.09.005. Epub 2013 Sep 17.
7
Development of M1 mAChR allosteric and bitopic ligands: prospective therapeutics for the treatment of cognitive deficits.M1 mAChR 变构和双位点配体的开发:治疗认知障碍的潜在治疗方法。
ACS Chem Neurosci. 2013 Jul 17;4(7):1026-48. doi: 10.1021/cn400086m. Epub 2013 May 23.

本文引用的文献

1
Quinolizidinone carboxylic acids as CNS penetrant, selective m1 allosteric muscarinic receptor modulators.喹诺里西啶酮羧酸作为中枢神经系统渗透剂,选择性M1变构毒蕈碱受体调节剂。
ACS Med Chem Lett. 2010 Jun 4;1(6):263-7. doi: 10.1021/ml100095k. eCollection 2010 Sep 9.
2
Chemical modification of the M(1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode.化学修饰 M(1)激动剂 VU0364572 揭示了药理学中的分子开关和双位结合模式。
ACS Chem Neurosci. 2012 Dec 19;3(12):1025-36. doi: 10.1021/cn300103e. Epub 2012 Sep 9.
3
Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models.新型 M1 毒蕈碱型乙酰胆碱受体变构激动剂诱导出与动物模型中的行为效应相对应的脑区特异性反应。
J Neurosci. 2012 Jun 20;32(25):8532-44. doi: 10.1523/JNEUROSCI.0337-12.2012.
4
Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.七跨膜受体的变构调节:理论、实践及中枢神经系统药物发现的机遇
J Med Chem. 2012 Feb 23;55(4):1445-64. doi: 10.1021/jm201139r. Epub 2012 Jan 6.
5
Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system.新型亚型选择性变构激动剂的发现与表征,用于研究中枢神经系统中M(1)受体的功能
ACS Chem Neurosci. 2010;1(2):104-121. doi: 10.1021/cn900003h.
6
Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071.从 MLPCN 探针 ML071 中开发出一种高选择性、可口服和可穿透中枢神经系统的 M1 激动剂。
Bioorg Med Chem Lett. 2011 Nov 1;21(21):6451-5. doi: 10.1016/j.bmcl.2011.08.084. Epub 2011 Aug 24.
7
Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold.基于喹诺利定酮羧酸骨架发现具有合适开发特性的选择性变构 M1 受体调节剂。
J Med Chem. 2011 Jul 14;54(13):4773-80. doi: 10.1021/jm200400m. Epub 2011 Jun 17.
8
"Molecular switches" on mGluR allosteric ligands that modulate modes of pharmacology.调节药理学模式的 mGluR 变构配体上的“分子开关”。
Biochemistry. 2011 Apr 5;50(13):2403-10. doi: 10.1021/bi200129s. Epub 2011 Mar 4.
9
Quinolizidinone carboxylic acid selective M1 allosteric modulators: SAR in the piperidine series.喹诺利定酮羧酸选择性 M1 变构调节剂:哌啶系列中的 SAR。
Bioorg Med Chem Lett. 2011 Mar 15;21(6):1710-5. doi: 10.1016/j.bmcl.2011.01.094. Epub 2011 Jan 28.
10
Discovery and optimization of a novel, selective and brain penetrant M1 positive allosteric modulator (PAM): the development of ML169, an MLPCN probe.发现并优化一种新型、选择性和可穿透血脑屏障的 M1 正变构调节剂 (PAM):MLPCN 探针 ML169 的研发。
Bioorg Med Chem Lett. 2011 May 1;21(9):2697-701. doi: 10.1016/j.bmcl.2010.12.015. Epub 2010 Dec 9.

进一步探索 M₁别构激动剂:细微的结构变化会消除 M₁别构激动作用,并导致pan-MAChR 正构拮抗剂作用。

Further exploration of M₁ allosteric agonists: subtle structural changes abolish M₁ allosteric agonism and result in pan-mAChR orthosteric antagonism.

机构信息

Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.

出版信息

Bioorg Med Chem Lett. 2013 Jan 1;23(1):223-7. doi: 10.1016/j.bmcl.2012.10.132. Epub 2012 Nov 9.

DOI:10.1016/j.bmcl.2012.10.132
PMID:23200253
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3525729/
Abstract

This letter describes the further exploration of two series of M(1) allosteric agonists, TBPB and VU0357017, previously reported from our lab. Within the TPBP scaffold, either electronic or steric perturbations to the central piperidine ring led to a loss of selective M(1) allosteric agonism and afforded pan-mAChR antagonism, which was demonstrated to be mediated via the orthosteric site. Additional SAR around a related M(1) allosteric agonist family (VU0357017) identified similar, subtle 'molecular switches' that modulated modes of pharmacology from allosteric agonism to pan-mAChR orthosteric antagonism. Therefore, all of these ligands are best classified as bi-topic ligands that possess high affinity binding at an allosteric site to engender selective M(1) activation, but all bind, at higher concentrations, to the orthosteric ACh site, leading to non-selective orthosteric site binding and mAChR antagonism.

摘要

这封信描述了我们实验室之前报道的 M(1)变构激动剂 TBPB 和 VU0357017 的两个系列的进一步探索。在 TPBP 支架内,对中央哌啶环进行电子或空间位阻修饰会导致选择性 M(1)变构激动作用丧失,并产生泛 M(1)mAChR 拮抗作用,这被证明是通过正位点介导的。在相关 M(1)变构激动剂家族(VU0357017)的周边进一步 SAR 研究确定了类似的、微妙的“分子开关”,这些开关调节了药理学模式,从变构激动作用转变为泛 M(1)mAChR 正位拮抗作用。因此,所有这些配体最好被归类为双靶配体,它们在变构位点具有高亲和力结合,从而产生选择性 M(1)激活,但在较高浓度下,所有配体都结合到正位 ACh 位点,导致非选择性正位结合和 mAChR 拮抗作用。